Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

Journal of Clinical Investigation

Volumn 93, Issue 1, 1994, Pages 63-69

  Black, Larry J ^a   Sato, Masahiko ^a   Rowley, Ellen R ^a   Magee, David E ^a   Bekele, Aster ^a   Williams, Daniel C ^a   Cullinan, George J ^a   Bendele, Raymond ^a   Kauffman, Raymond F ^a   Bensch, William R ^a   Frolik, Charles A ^a   Termine, John D ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

antiestrogen; benzothiophene; DEXA; estrogen; ethynyl estradiol

Indexed keywords

ETHINYLESTRADIOL; RALOXIFENE; ALKALINE PHOSPHATASE; ANTIESTROGEN; CALCIUM; CHOLESTEROL; PHOSPHORUS; PIPERIDINE DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FEMUR; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; RAT; TIBIA; UTERUS; ANIMAL; BLOOD; BODY WEIGHT; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; EPITHELIUM; EPITHELIUM CELL; HYPERTROPHY; OSTEOLYSIS; PATHOLOGY; RAT STRAIN;

ADMINISTRATION, ORAL; ALKALINE PHOSPHATASE; ANIMAL; BODY WEIGHT; BONE DENSITY; BONE RESORPTION; CALCIUM; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; EPITHELIUM; ESTROGEN ANTAGONISTS; ETHINYL ESTRADIOL; FEMALE; HYPERTROPHY; OVARIECTOMY; PHOSPHORUS; PIPERIDINES; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; UTERUS;

EID: 0028167482     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI116985     Document Type: Article

References (45)

1. Consensus Conference. Osteoporosis. 1984. J. Am. Med. Assoc. 252:799-802.
2. Riggs, B. L. 1991. Overview of osteoporosis. West. J. Med. 154:63-77.
3. Gordon, T., W. B. Kannel, M. C. Hjortland, and P. M. McNamara. 1978. Menopause and coronary heart disease: The Framingham Study. Ann. Int. Med. 89:157-161.
4. Matthews, K. A., E. Meilahn, L. H. Kuller, S. F. Kelsey, A. W. Cagguila, and R. R. Wing. 1989. Menopause and risk factors for coronary heart disease. N. Engl. J. Med. 321:641-646.
5. Cummings, S. R. 1991. Evaluating the benefits and risks of postmenopausal hormone therapy. Am J. Med. 91(Suppl. 5B):14S-18S.
6. Judd, H. L., D. R. Meldrum, L. J. Deftos, and B. E. Henderson. 1983. Estrogen replacement therapy: Indications and complications. Ann. Int. Med. 98:195-205.
7. Henderson, B. E., R. K. Ross, and M. C. Pike. 1993. Hormonal chemoprevention of cancer in women. Science (Wash. DC). 259:633-638.
8. Overgaard, K., M. A. Hansen, S. B. Jensen, and C. Christiansen. 1992. Effect of salcatonin given imranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. Br. Med. J. 305:556-561.
9. Fromm, G. A., E. Vega, L. Plantalech, A. M. Galich, and C. A. Mautalen. 1991. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int. 1:129-133.
10. Choice of drugs for postmenopausal osteoporosis. 1992. The Medical Leiter On Drugs and Therapeutics 34:101-102.
11. Love, R. R., R. B. Mazess, H. S. Barden, S. Epstein, P. A. Newcomb, V. C. Jordan, P. P. Carbone, and D. L. DeMets. 1992. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326:852-856.
12. Love, R. R., D. A. Wiebe, P. A. Newcomb, L. Cameron, H. Leventhal, V. C. Jordan, J. Feyzi, and D. L. DeMets. 1991. Effects of tamoxifen on cardiovascular risk factors in post-menopausal women. Ann. Intern Med. 115:860-864.
13. Love, R. R., L. Cameron, B. L. Connell, and H. Leventhal. 1991. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch. Intern. Med. 151:1842-1847.
14. Kurl, R. N., and N. M. Borthwiek. 1980. Clomiphene and tamoxifen action in the rat uterus. J. Endocrinol. 85:519-524.
15. Jones, C. D., T. Suarez, E. H. Massey, L. J. Black, and F. C. Tinsley. 1979. Synthesis and anti-estrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl) ethoxy]-phenyl] methanone, methanesulfonic acid salt. J. Med. Chem. 22:962-966.
16. Wronski, T. J., and C.-F. Yen. 1991. The ovariectomized rat as an animal model for postmenopausal bone loss. Cells Mater. (Suppl. 1):69-74.
17. Kalu, D. N., C. C. Liu, E. Salerno, B. Mollis, R. Echon, and M. Ray. 1991. Skeletal response of ovariectomized rats to low and high doses of 17β-estradiol. Bone Miner. 14:175-187.
18. Wronski, T. J., C.-F. Yen, K. W. Burton, R. C. Mehta, P. S. Newman. E. E. Soltis, and P. P. DeLuca. 1991. Skeletal effects of calcitonin in ovariectomized rats. Endocrinology. 129:2246-2250.
19. Seedor, J. G., H. A. Quartuccio, and D. D. Thompson. 1991. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J. Bone Miner. Res. 6:339-346.
20. Turner R. T., G. K. Wakely, K. S. Hannon, and N. H. Bell. 1988. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology. 122:1146-1150.
21. Staels, B., J. Auwerx, L. Chan, A. von Tol, M. Rosseneu, and G. Verhoevem. 1989. Influence of development, estrogens, and food intake on apolipoprotein A-I. A-II and E mRNA in rat liver and intestine. J. Lipid Res. 30:1137-1145.
22. Donati, R. J., P. V. Harper, A. Hughes, and R. V. Hay. 1990. Serum cholesterol- and apoprotein B-lowering effects of cis-tamoxifen. Arteriosclerosis. 10:822A.
23. Wiebe, D. A., and J. T. Bernert. 1984. Influence of incomplete cholesteryl ester hydrolysis on enzymatic measurements of cholesterol. Clin. Chem. 30:352-356.
24. Bucolo, G., and H. David. 1973. Quantitative determination of serum trigycerides by the use of enzymes. Clin. Chem. 19:476-482.
25. Roudebush, R. E., D. E. Magee, D. N. Benslay, A. M. Bendele, and H. U. Bryant. 1993. Effect of weight manipulation on bone loss due to ovariectomy and the protective effects of estrogen in the rat. Calcif. Tissue Int. 53:61-64.
26. Ammann, P., R. Rizzoli, D. Slosman, and J. P. Bonjour. 1992. Sequential and precise in vivo measurement of bone mineral density in rats using dual energy x-ray absorptiometry. J. Bone Miner. Res. 7:311-316.
27. Griffen, M. G., R. Kimble, W. Hopfer, and R. Pacifici. 1993. Dual energy x-ray absorptiometry of the rat: Accuracy, precision and measurement of bone loss. J. Bone Miner. Res. 8:795-800.
28. Kalu, D. N. 1991. The ovariectomized rat model of post-menopausal bone loss. Bone Miner. 15:175-192.
29. Wronski, T. J., M. Cintron, A. L. Doherty, and L. M. Dann. 1988. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rate. Endocrinology. 123:681-686.
30. Jordan, V. C., E. Phelps, and J. U. Lindgren. 1987. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 10:31-35.
31. Turner, R. T., G. L. Evans, and G. K. Wakely. 1993. Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: Inhibition of indices of formation and resorption. J. Bone Miner. Res. 8:359-366.
32. Evans, G., H. U. Bryant, M. Sato, and R. T. Turner. 1993. Raloxifene is a tissue specific estrogen agonist. J. Bone Miner. Res. 8(Suppl. 1):S134.
33. Beall, P. T., L. K. Misra, R. L. Young, H. J. Spjut, H. J. Evans, and A. LeBlanc. 1984. Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcif. Tissue Int. 36:123-125.
34. Moon, L. Y., G. K. Wakely, and R. T. Turner. 1991. Dose-dependent effects of tamoxifen on long bones in growing rats: Influence of ovarian steroids. Endocrinology. 129:1568-1574.
35. Ma P. T. S., T. Yamamoto, J. L. Goldstein, and M. S. Brown. 1986. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17-α-ethinyl estradiol. Proc. Natl. Acad. Sci. USA. 83:792-796.
36. Chao, Y., E. E. Windler, G. C. Chen, and R. J. Havel. 1979. Hepatic catabolism of rat and human lipoproteins in rats treated with 17-α-ethinyl estradiol. J. Biol. Chem. 254:11360-11366.
37. Brown, M. S., and J. L. Goldstein. 1980. The estradiol-stimulated lipoprotein receptor of rat liver. J. Biol. Chem. 255:10464-10471.
38. Walsh B. W., I. Schiff, B. Rosner, L. Greenberg, V. Ravnikar, and F. M. Sacks. 1991. Effects of post-menopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325:1196-1204.
39. Draper, M. W., D. E. Flowers, W. J. Huster, and J. A. Nield. 1993. Effects of raloxifene (LY139481 HCl) on biochemical markers of bone and lipid metabolism in healthy post-menopausal women. In Proceedings of the Fourth International Symposium on Osteoporosis, Hong Kong. In press.
40. Jordan, V. C. K. E. Allen, and C. J. Dix. 1980. Pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep. 64:745-759.
41. Black, L. J.,C. D. Jones, and J. F. Falcone. 1983. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 32:1031-1036.
42. Szego, C. and S. Roberts. 1953. Steroid action and interactions in uterine metabolism. Recent Prog. Horm. Res. 8:419-468.
43. Black, L. J., C. D. Jones, J. H. Clark, and J. A. Clemens. 1982. LY156758: A unique anti-estrogen displaying high affinity for estrogen receptors, negligible estrogenic acitivity and near-total estrogen antagonism in vivo. Breast Cancer Res. Treat. 2:279.
44. Glasebrook, A. L., D. L. Phillips, and J. P. Sluka. 1993. Multiple binding sites for the anti-estrogen raloxifene. J. Bone Miner. Res. 8(Suppl. 1):S268.
45. Yang, N. N., S. Hardikar, J. Kim, and M. Sato. 1993. Raloxifene, an anti-esfogen, simulates the effects of estrogen on inhibiting bone resorption through regulating TGFβ-3 expression in bone. J. Bone Miner. Res. 8(Suppl. 1):S118.